Chronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary disease with (acute) exacerbation
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive single dose of 20 mg furosemide from Abu Raihan Pharmaceutical Company (Iran) during the first 15 minutes of treatment in the fo
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age at least 18 years Informed consent to participate in the study Previous chronic obstructive pulmonary disease Definitive diagnosis of exacerbation of chronic obstructive pulmonary disease
Exclusion criteria
Exclusion criteria: Other respiratory disease comorbidity Patients treated with oral or intravenous furosemide Patients who are contraindicated in furosemide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in blood oxygen saturation. Timepoint: Before starting treatment and 24 hours after starting treatment. Method of measurement: Pulse oximeter.;Heart rate. Timepoint: Before starting treatment and 24 hours after starting treatment. Method of measurement: Counting beats per minute by touching the inside of the wrist near the thumb for one minute.;Peak respiratory capacity. Timepoint: Before starting treatment and 24 hours after starting treatment. Method of measurement: Using a spirometry device.;Severity ofdyspnea. Timepoint: Before starting treatment and 24 hours after starting treatment. Method of measurement: With the BORG scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood respiratory gas levels (PO2, HCO3, SO2, Ph, and PCO2). Timepoint: Before treatment and 24 hours after starting treatment. Method of measurement: Blood Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohreh Kahramfar
Hamedan University of Medical Sciences
Outcome results
None listed